Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,972 shares of the company's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $34.15, for a total value of $67,343.80. Following the completion of the sale, the insider now owns 87,720 shares in the company, valued at $2,995,638. The trade was a 2.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Castle Biosciences Trading Down 7.3 %
Shares of CSTL traded down $2.25 during mid-day trading on Friday, reaching $28.58. The company had a trading volume of 177,806 shares, compared to its average volume of 325,046. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The stock has a market cap of $800.53 million, a price-to-earnings ratio of 142.91 and a beta of 0.99. The firm has a fifty day simple moving average of $31.16 and a 200-day simple moving average of $26.21. Castle Biosciences, Inc. has a fifty-two week low of $16.97 and a fifty-two week high of $35.84.
📉 Warning: Market Crash Predicted - Secure Your Savings
From Behind the Markets | Ad
The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.
Take these 4 steps to protect your retirement here >>>
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. During the same quarter last year, the company earned ($0.26) earnings per share. On average, sell-side analysts anticipate that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Castle Biosciences
A number of hedge funds have recently made changes to their positions in CSTL. Bellevue Group AG raised its stake in Castle Biosciences by 3.7% during the 3rd quarter. Bellevue Group AG now owns 1,262,030 shares of the company's stock valued at $35,993,000 after acquiring an additional 44,929 shares in the last quarter. Townsquare Capital LLC lifted its stake in Castle Biosciences by 25.2% during the third quarter. Townsquare Capital LLC now owns 23,270 shares of the company's stock valued at $664,000 after buying an additional 4,688 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new position in shares of Castle Biosciences in the third quarter worth about $312,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Castle Biosciences in the third quarter worth approximately $1,252,000. Finally, Algert Global LLC raised its holdings in shares of Castle Biosciences by 0.4% during the third quarter. Algert Global LLC now owns 134,321 shares of the company's stock valued at $3,831,000 after acquiring an additional 599 shares during the period. Institutional investors own 92.60% of the company's stock.
Wall Street Analyst Weigh In
CSTL has been the subject of a number of recent analyst reports. Scotiabank boosted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research report on Wednesday, November 6th. KeyCorp upped their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Lake Street Capital lifted their target price on Castle Biosciences from $34.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Robert W. Baird increased their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. Finally, Stephens restated an "overweight" rating and issued a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $37.88.
Check Out Our Latest Stock Analysis on CSTL
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
